FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4306925101> ?p ?o ?g. }

• W4306925101 abstract "Abstract Background Clinically, muscular dystrophy (MD), especially in Charcot-Marie-Tooth (CMT)-associated MD, still lacks effective treatment. Deletion and mutation of L-periaxin can be involved in CMT4F by destroying the myelin sheath form, which may be related to the inhibitory role of ezrin in the self-association of L-periaxin. However, it is still unknown whether L-periaxin and Ezrin are independently or interactively involved in the process of MD by affecting the function of muscle satellite cells. Method A gastrocnemius muscle (GA) atrophy model was prepared to mimic CMT4F and its associated muscle atrophy by mechanical clamping of the peroneal nerve. Differentiating C2C12 myoblast cells treated with Ad-ezrin or Ad-shezrin were detected by RNA-seq, Q-PCR, immunofluorescence staining and Western blotting. Ad-periaxin, Ad-shperiaxin, Ad-NFATc1/c2 or Ad-shNFATc3/c4 were used to confirm their role in ezrin-mediated myoblast differentiation, myotube formation and GA repair in a peroneal nerve injury model. Results For the first time, instantaneous L-periaxin expression was highest on the 6 th day, while Ezrin expression peaked on the 4 th day during myoblast differentiation/fusion in vitro . In vivo transduction of Ad-ezrin, but not Ad-ezrin, into the gastrocnemius muscle (GA) in a peroneal nerve injury model increased the numbers of MyHC-I + and MyHC-II + myofibers, reducing muscle atrophy and fibrosis. Local muscle injection of Ad-ezrin combined with incubation of Ad-shperiaxin within the injured peroneal nerve or injection of Ad-shperiaxin into PNI-injured GA not only increased the number of muscle fibers but also recovered its size to a relatively normal level in vivo. Overexpression of Ezrin promoted myoblast differentiation/fusion, inducing increased MyHC-I + and MyHC-II + muscle fiber specialization, and the specific effects could be enhanced by the addition of Ad-shPeriaxin. Overexpression of L-periaxin did not alter the inhibitory effects on myoblast differentiation and fusion mediated by Ad-shEzrin in vitro but decreased myotube length and size. Mechanistically, Ad-Ezrin did not alter PKA-γ cat, PKA reg Iα and Iβ levels, but increase PKA-α cat and PKA reg II α levels, leading to the decreased ratio of PKA reg I/II. The PKA inhibitor H-89 remarkably abolished the overexpression effects of Ezrin on increased myoblast differentiation/fusion. In contrast, knockdown of Ezrin by shRNA significantly delayed myoblast differentiation/fusion accompanied by a increased PKA reg I/II ratio, and the inhibitory effects could be eliminated by the PKA reg activator N6-Bz-cAMP. Meanwhile, Ad-ezrin enhanced type I muscle fiber specialization, accompanied by increase in NFATc2/c3 levels and decrease in NFATc1. Furthermore, Ad-NFATc2 or Ad-shNFATc3 reversed the inhibitory effects of Ad-shEzrin on myoblast differentiation/fusion. Conclusions The spatiotemporal pattern of Ezrin/Periaxin expression was involved in the control of myoblast differentiation/fusion, myotube length and size, and myofiber specialization, which was related to the activated PKA-NFAT-MEF2C signaling pathway, providing a novel L-Periaxin/ezrin joint strategy for the treatment of MD induced by nerve injury, especially in CMT4F." @default.
• W4306925101 created "2022-10-21" @default.
• W4306925101 creator A5003065832 @default.
• W4306925101 creator A5003642180 @default.
• W4306925101 creator A5004366207 @default.
• W4306925101 creator A5012324763 @default.
• W4306925101 creator A5017437960 @default.
• W4306925101 creator A5025058810 @default.
• W4306925101 creator A5030547852 @default.
• W4306925101 creator A5031372799 @default.
• W4306925101 creator A5032881192 @default.
• W4306925101 creator A5040115773 @default.
• W4306925101 creator A5043490236 @default.
• W4306925101 creator A5044199370 @default.
• W4306925101 creator A5045035938 @default.
• W4306925101 creator A5049373243 @default.
• W4306925101 creator A5062703263 @default.
• W4306925101 creator A5066935614 @default.
• W4306925101 creator A5077544471 @default.
• W4306925101 creator A5078902336 @default.
• W4306925101 creator A5083663683 @default.
• W4306925101 creator A5091214313 @default.
• W4306925101 date "2022-10-20" @default.
• W4306925101 modified "2023-10-18" @default.
• W4306925101 title "The spatiotemporal matching pattern of Ezrin/Periaxin involved in myoblast differentiation and fusion and Charcot-Marie-Tooth-associated muscle atrophy" @default.
• W4306925101 cites W1533465487 @default.
• W4306925101 cites W1980811848 @default.
• W4306925101 cites W2005252392 @default.
• W4306925101 cites W2005470018 @default.
• W4306925101 cites W2005510844 @default.
• W4306925101 cites W2012049187 @default.
• W4306925101 cites W2017075649 @default.
• W4306925101 cites W2033561732 @default.
• W4306925101 cites W2043445408 @default.
• W4306925101 cites W2061994372 @default.
• W4306925101 cites W2062892825 @default.
• W4306925101 cites W2065556248 @default.
• W4306925101 cites W2087224286 @default.
• W4306925101 cites W2097041188 @default.
• W4306925101 cites W2127177109 @default.
• W4306925101 cites W2144274867 @default.
• W4306925101 cites W2148736421 @default.
• W4306925101 cites W2159721645 @default.
• W4306925101 cites W2166416342 @default.
• W4306925101 cites W2167842460 @default.
• W4306925101 cites W2171198485 @default.
• W4306925101 cites W2346123264 @default.
• W4306925101 cites W2602054505 @default.
• W4306925101 cites W2754011681 @default.
• W4306925101 cites W2789901330 @default.
• W4306925101 cites W2790410575 @default.
• W4306925101 cites W2797609680 @default.
• W4306925101 cites W2807199482 @default.
• W4306925101 cites W2894358495 @default.
• W4306925101 cites W2909421659 @default.
• W4306925101 cites W2915277235 @default.
• W4306925101 cites W2993556246 @default.
• W4306925101 cites W2999363620 @default.
• W4306925101 cites W3086698680 @default.
• W4306925101 doi "https://doi.org/10.21203/rs.3.rs-2143901/v1" @default.
• W4306925101 hasPublicationYear "2022" @default.
• W4306925101 type Work @default.
• W4306925101 citedByCount "0" @default.
• W4306925101 crossrefType "posted-content" @default.
• W4306925101 hasAuthorship W4306925101A5003065832 @default.
• W4306925101 hasAuthorship W4306925101A5003642180 @default.
• W4306925101 hasAuthorship W4306925101A5004366207 @default.
• W4306925101 hasAuthorship W4306925101A5012324763 @default.
• W4306925101 hasAuthorship W4306925101A5017437960 @default.
• W4306925101 hasAuthorship W4306925101A5025058810 @default.
• W4306925101 hasAuthorship W4306925101A5030547852 @default.
• W4306925101 hasAuthorship W4306925101A5031372799 @default.
• W4306925101 hasAuthorship W4306925101A5032881192 @default.
• W4306925101 hasAuthorship W4306925101A5040115773 @default.
• W4306925101 hasAuthorship W4306925101A5043490236 @default.
• W4306925101 hasAuthorship W4306925101A5044199370 @default.
• W4306925101 hasAuthorship W4306925101A5045035938 @default.
• W4306925101 hasAuthorship W4306925101A5049373243 @default.
• W4306925101 hasAuthorship W4306925101A5062703263 @default.
• W4306925101 hasAuthorship W4306925101A5066935614 @default.
• W4306925101 hasAuthorship W4306925101A5077544471 @default.
• W4306925101 hasAuthorship W4306925101A5078902336 @default.
• W4306925101 hasAuthorship W4306925101A5083663683 @default.
• W4306925101 hasAuthorship W4306925101A5091214313 @default.
• W4306925101 hasBestOaLocation W43069251011 @default.
• W4306925101 hasConcept C105702510 @default.
• W4306925101 hasConcept C142669718 @default.
• W4306925101 hasConcept C142724271 @default.
• W4306925101 hasConcept C1491633281 @default.
• W4306925101 hasConcept C199096232 @default.
• W4306925101 hasConcept C207200792 @default.
• W4306925101 hasConcept C2776263037 @default.
• W4306925101 hasConcept C2780246058 @default.
• W4306925101 hasConcept C2781172350 @default.
• W4306925101 hasConcept C55493867 @default.
• W4306925101 hasConcept C71924100 @default.
• W4306925101 hasConcept C86803240 @default.
• W4306925101 hasConcept C95444343 @default.
• W4306925101 hasConceptScore W4306925101C105702510 @default.
• W4306925101 hasConceptScore W4306925101C142669718 @default.

• next